DermaSensor is a biotechnology startup founded in 2009, with a mission to revolutionize skin cancer evaluations and reduce healthcare costs. Their innovative approach addresses the lack of accessible skin cancer checks for a majority of Americans. The company's flagship product is a handheld device that utilizes machine learning and spectroscopy to provide quick and objective assessments of skin lesions for potential cancer within seconds.
DermaSensor recently received a significant boost with a $10.00M Series A investment on 15 June 2022. The investors in this round include prominent names such as Ceros Capital Markets, Maurice Ferre, M.D., Ernest Bachrach, and Alberto Beeck.
By leveraging cutting-edge technology and a focus on the critical healthcare and medical devices industries, DermaSensor has positioned itself as a key player in advancing skin cancer evaluations, making it an attractive prospect for potential venture capital investors.
